For years, the path to a “billion-dollar movie” ran directly through Beijing. Hollywood studios viewed the Chinese market not just as a bonus, but as a kingmaker—a theatrical engine capable of turning a modest hit into a global phenomenon. But that era of undisputed influence has evaporated, replaced by a complex landscape where American blockbusters are increasingly treated as optional supplements rather than main events.
The shift is visible in the raw data. In 2019, the Chinese box office was a gold mine for U.S. Studios, with nine American titles each earning more than $100 million. The peak of this era was Disney and Marvel’s “Avengers: Endgame,” which hauled in more than $600 million in the region. Today, that dominance is a memory. Over the last five years, only 10 American films have crossed the $100 million threshold in China, and only two have managed to surpass $200 million.
While some may point to the pandemic as the sole culprit, the decline is the result of a systemic decoupling. From the expiration of diplomatic agreements to a surge in high-quality homegrown cinema, the China box office is no longer the reliable safety net it once was for Hollywood’s biggest bets.
Posters of films are on display at a cinema in Shanghai, Aug. 31, 2025.
Vcg | Visual China Group | Getty Images
The collapse of the diplomatic safety net
The structural relationship between Hollywood and Chinese cinemas changed fundamentally years before the pandemic. In 2012, the two governments struck a U.S.-China Film Agreement that guaranteed the release of 34 American films in China annually. This pact provided a predictable pipeline for distribution and a level of market access that studios had previously struggled to secure.
However, that agreement ended in 2017 and was never renewed. In the vacuum that followed, the Chinese government gained more leverage over which films entered the market, and when. The China Film Administration began implementing “blackout dates”—strategic windows where foreign films are barred from release to ensure local titles have an unobstructed path to the audience.
This administrative control allows the state to treat foreign cinema as a variable rather than a constant. Aynne Kokas, a professor at the University of Virginia and author of “Hollywood Made in China,” notes that the film bureau effectively turns the levers of distribution on and off based on market needs. When local films are performing well, the gates for foreign content close; when there is a gap in the schedule, the market opens slightly.
The regulatory hurdle
Beyond the timing of releases, the content itself faces an increasingly rigorous gauntlet. Strict censorship policies mean that every frame must be approved by the film bureau before distribution is even considered. This creates a volatile environment for studios; a film can be completed and marketed in the U.S., only to be quietly shelved or heavily edited in China, rendering the original international marketing strategy obsolete.
A mismatch in intellectual property
There is also a growing cultural divide in what audiences actually want to see. For a long time, Hollywood assumed that “big” IP in the U.S. Would automatically translate to “big” IP in China. The reality has proven far more nuanced.
Nostalgia, a powerful driver of ticket sales in North America, does not always travel. A prime example is the “Star Wars” franchise. When the sequel trilogy arrived in 2015, it struggled in China because the original and prequel trilogies had never been widely released in the region. Without a childhood connection to the characters, Chinese audiences had little incentive to invest in the new installments.
A similar disconnect occurred with “The Super Mario Bros. Movie.” While the film was a global juggernaut, earning more than $1.3 billion globally in 2023, it earned only $25 million in China. The disconnect stems from a difference in gaming culture; the console-based nostalgia that drove $575 million in U.S. Domestic sales simply didn’t exist in a market where mobile gaming dominates.
| Metric | 2019 (Peak Era) | Post-Pandemic (Last 5 Years) |
|---|---|---|
| Films > $100M | 9 Titles | 10 Titles (Total) |
| Top Performer | Avengers: Endgame (>$600M) | Zootopia 2 ($650M) |
| Market Status | Strategic Kingmaker | Unpredictable Anomaly |
The rise of the ‘Visual Spectacle’
Despite the slump, certain types of American films still find a footing. The current appetite in the region leans heavily toward apolitical, high-concept visual spectacles. Films that rely on “eye candy” and action rather than complex narrative lore or specific Western cultural touchstones tend to perform better.
Recent successes include the “Fast & Furious” saga, “Jurassic World,” and the “Godzilla x Kong” franchise. These films offer a universal cinematic language that bypasses the require for deep-seated nostalgia or political alignment, making them the safest bets for studios seeking a Chinese payout.
Even with these hurdles, the potential for a massive hit keeps studios engaged. Disney’s “Zootopia 2” serves as a recent outlier, tallying a record-breaking $650 million following its 2025 release. However, analysts warn that What we have is an anomaly rather than a trend. Wall Street and studio executives are cautioned against expecting a broad resurgence of ticket sales for American fare.
What remains on the horizon
Hollywood continues to test the waters, though the strategy has shifted from dependence to opportunistic experimentation. The upcoming slate for China includes Universal’s “The Super Mario Galaxy Movie,” “Michael,” and Warner Bros.’ “Mortal Kombat II,” as well as Disney’s “The Devil Wears Prada 2.”
Industry analysts also expect “Toy Story 5,” “Dune: Part Three,” and “Avengers: Doomsday” to target Chinese theaters this year. However, because of the censorship process, these releases are not guaranteed. Unlike the domestic U.S. Slate, the Hollywood schedule in China remains fluid and subject to the whims of the film bureau.
The bottom line for the industry is a shift in risk management. China remains a massive opportunity—potentially worth hundreds of millions of dollars—but it is no longer a guaranteed pillar of a film’s financial success. As Paul Dergarabedian, head of marketplace trends at Comscore, suggests, the appetite for big Hollywood movies exists, but the access to that appetite is now strictly controlled.
The next major indicator of the market’s health will be the performance of the upcoming summer franchise launches, which will reveal whether “Zootopia 2” was a fluke or the start of a new, more selective era of distribution.
Do you think Hollywood should stop tailoring movies for the Chinese market? Share your thoughts in the comments.
